



[Home](#) [About](#) [Products & Services](#) [Contact Us](#)

**American Heart Journal**

[Current Issue](#) [Archive](#)

**Search:**

**GO**

[Advanced Search](#)

### Ovid News

[Learn](#) about Ovid's new research content and products.

### Ovid Events

Check out where Ovid is across the globe at industry conferences and events worldwide.

### Are you affiliated with a leading medical or academic institution?

If so, send your librarian an email recommending titles you've found valuable for research at your institution.

**August 1999, 138:2, Part 2 > Advances in antithrombotic therapy...**

### ARTICLE LINKS:

[Fulltext](#)

**Advances in antithrombotic therapy of acute myocardial infarction.**

**The Dawn Of A New Era In The Treatment Of Acute Myocardial Infarction**

American Heart Journal. 138(2, Part 2) Supplement:S171-S176, August 1999.  
*Gensini, G. F. MD; Comeglio, M. MD; Falai, M. MD*

### Abstract:

The aim of the acute treatment of myocardial infarction is to restore, as promptly as possible, blood flow to the infarcted vessel. Thrombolysis is a cornerstone of treatment, and direct coronary angioplasty (PTCA) even better alternative reperfusion strategy. The activation of hemostasis after plaque disruption represents a strong rationale for the use of antithrombotic drugs. The results of the ISIS-2 to Antiplatelet Trialists' Collaboration indicated that aspirin is mandatory in patients with acute secondary prevention. Recently, the efficacy of abciximab and other glycoprotein IIb/IIIa inhibitors in treatment of acute coronary syndromes and after PTCA, and their early use in patients with infarction is presently under evaluation. Anticoagulation with heparin appears to be only slightly effective in patients with infarction not treated with thrombolysis; however, a rationale exists for its use in patients undergoing and/or surgical revascularization and in conjunction with fibrin-specific thrombolytic agents. The possible usefulness of low-molecular-weight heparin. Direct antithrombin agents have been recently studied as an adjunct to thrombolysis. The data from these studies indicate a narrow therapeutic window, with only marginal advantage over heparin; studies with newer compounds are still a mandatory drug in patients with acute myocardial infarction; the most promising agent is glycoprotein IIb/IIIa inhibitors. Heparin and low-molecular-weight heparins are indicated in studies are needed to assess the value of newer direct thrombin inhibitors.

(C) Mosby-Year Book Inc. 1999. All Rights Reserved.

Ads by Google

### Learn Wound

### Debridement

Conservative Sharp

Debridement Get

Competency

Documentation Now!

[www.sharpdebridement.com](http://www.sharpdebridement.com)

### Wanted: student

### authors

Earn 5 dollars a page

by making our textbook

abstracts.

[www.easyrecap.com](http://www.easyrecap.com)

Copyright © 2005, Ovid. All rights reserved.


Published by Ovid

[Copyright/Disclaimer Notice](#) || [Privacy Policy](#)

[Contact Ovid](#) || [Technical Support](#)



A service of the National Library of Medicine  
and the National Institutes of Health



All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for clopidogrel ridogrel

Limits Preview/Index History Clipboard Details

About Entrez  
NCBI Toolbar

Text Version

Entrez PubMed  
Overview  
Help | FAQ  
Tutorials  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
Special Queries  
LinkOut  
My NCBI

Related Resources  
Order Documents  
NLM Mobile  
NLM Catalog  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

**Note:** Performing your original search, *clopidogrel ridogrel*, in PubMed will retrieve 2 citations.

Display Abstract Show 20 Sort by Relevance Send to Clipboard

All: 1 Review: 1

☐ 1: Herz. 1996 Feb;21(1):44-59.

Related Articles, Links

## **-Differential antithrombotic therapy in patients with low and high PTCA risk-**

[Article in German]

**Silber S, Dorr R.**

Herzkatheterlabor der Kardiologischen Gemeinschaftspraxis, Klinik Dr. Muller, Munchen.

Acute coronary occlusion as well as restenosis still represent the major limitations of coronary interventions. Either event seems to be related to thrombus formation. The purpose of this overview is to summarize the current status of the usefulness of conventional and newer antithrombotic drugs regarding the prevention of acute occlusion and restenosis (excluding stents). **ANTICOAGULATION:** For ethical reasons, no placebo-controlled studies were conducted to prove the usefulness of heparin in preventing acute occlusions. The dosage mostly used is 10,000 U, although a relationship between dosage and complication rate has not been documented. A prolonged heparin infusion in patients with low risk and uncomplicated PTCA has no advantages. Restenosis is not influenced by prolonged infusion of heparin or administration of coumadin as well. Low molecular weight heparin is currently under investigation. Hirudin and hirulog have shown promising results with less acute occlusions; however, their therapeutic range must be considered. **ANTIAGGREGATION:** In controlled studies, ASA significantly reduced acute occlusions during PTCA when given in addition to heparin. Ticlopidin is as effective as ASA, but due to its side effects should only be administered when contraindications to ASA exist. ASA significantly reduced restenosis in only 1 of 4 studies with limited number of patients. Thromboxane inhibitors such as ridogrel or clopidogrel showed promising initial results. Trapidil significantly reduced restenosis in 2 studies; quantitative stenosis analysis, however, was not performed. Inhibition of platelets by glycoprotein (GP) IIb/IIIa receptor antagonists represents an innovative therapeutic concept: numerous controlled trials have documented a significant reduction in cardiac ischemic events and therefore indirectly in restenosis rates. The recombinant monoclonal antibody c7E3 Fab seems to be more effective than the synthetic integrilin. Unfortunately, efficacy appears to be in direct relationship to the risk of bleeding complications. The clinical role of oral GP IIb/IIIa inhibitors has yet to be established. For patients with high risk PTCA, the use of hirudin instead of heparin as well as the addition of GP IIb/IIIa inhibitors should be considered.

## Publication Types:

- [Review](#)

PMID: 8647579 [PubMed - indexed for MEDLINE]

---

Display  Show  Sort by  Send to

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

May 30 2006 06:41:35